{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:04:51Z","timestamp":1789322691518,"version":"build-2803163510"},"reference-count":42,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Recurrent erysipelas is a common and clinically significant condition that poses challenges for both patients and healthcare systems. Each episode may damage lymphatic vessels, leading to chronic lymphedema, which perpetuates the risk of further relapses. Recurrence rates remain high, ranging from 11% in outpatients during the first year to up to 46% of hospitalized patients within three years. The lower limbs are the most frequent site, although recurrences may also occur in other regions, such as the upper limb after mastectomy with lymph node dissection. This review summarizes current knowledge on risk factors, preventive measures, and chemoprophylaxis in recurrent erysipelas. Modifiable risk factors such as obesity, diabetes, venous insufficiency, tinea pedis, and poor hygiene play an important role, while non-modifiable factors include age, sex, and a history of prior episodes. Non-pharmacological strategies\u2014weight reduction, glycemic control, smoking cessation, compression therapy, and meticulous skin care\u2014form the cornerstone of prevention and may reduce the need for long-term antibiotics. Antibiotic prophylaxis, most commonly with oral penicillin V or intramuscular benzathine penicillin, has been shown to lower recurrence rates. However, efficacy may be reduced in patients with chronic edema or severe obesity. Macrolides serve as alternatives in penicillin-allergic patients, but concerns remain about resistance, adverse effects, and drug\u2013drug interactions. In conclusion, recurrent erysipelas requires a multifaceted approach. While antibiotic prophylaxis is effective, its long-term success depends on simultaneous management of underlying conditions. Further studies are needed to define optimal regimens, treatment duration, and non-antibiotic alternatives.<\/jats:p>","DOI":"10.3390\/biomedicines13102448","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:04:52Z","timestamp":1759925092000},"page":"2448","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recurrent Erysipelas: Clinical Challenges and Strategies for Prevention\u2014A Narrative Literature Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-6722","authenticated-orcid":false,"given":"Dominika","family":"Jask\u00f3\u0142a-Polkowska","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases and Allergology, Military Institute of Medicine-National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3393-4831","authenticated-orcid":false,"given":"Krystian","family":"Blok","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases and Allergology, Military Institute of Medicine-National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Skibi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases and Allergology, Military Institute of Medicine-National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-4124","authenticated-orcid":false,"given":"Andrzej","family":"Chcia\u0142owski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases and Allergology, Military Institute of Medicine-National Research Institute, 128 Szaser\u00f3w Street, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"ref_1","unstructured":"Leszczyszyn-Pynka, M. (2025). Erysipelas. Interna Szczeklika 2025, Medycyna Praktyczna. [19th ed.]."},{"key":"ref_2","first-page":"1307232","article-title":"In Search of Risk Factors for Recurrent Erysipelas and Cellulitis of the Lower Limb: A Cross-Sectional Study of Epidemiological Characteristics of Patients Hospitalized due to Skin and Soft-Tissue Infections","volume":"2020","author":"Krankowska","year":"2020","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/QCO.0000000000001096","article-title":"Recurrence of skin and soft tissue infections: Identifying risk factors and treatment strategies","volume":"38","author":"Toschi","year":"2025","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Inghammar, M., Rasmussen, M., and Linder, A. (2014). Recurrent erysipelas-risk factors and clinical presentation. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-270"},{"key":"ref_5","unstructured":"Michael, Y., and Shaukat, N.M. (2025, August 30). Erysipelas, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532247\/."},{"key":"ref_6","unstructured":"National Institute for Health and Care Excellence (NICE) (2025, August 30). Cellulitis and Erysipelas: Antimicrobial Prescribing. NICE Guideline NG141, UK, 27 September 2019. Available online: https:\/\/www.nice.org.uk\/guidance\/ng141."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.2147\/IJGM.S326459","article-title":"Recurrent Cellulitis: Who is at Risk and How Effective is Antibiotic Prophylaxis?","volume":"15","author":"Ong","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_8","unstructured":"Boucher, H. (2025). Erysipelas, Recurrent, Lymphedema. Sanford Guide to Antimicrobial Therapy [Mobile App], Antimicrobial Therapy, Inc."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Li, A., Wang, N., Ge, L., Xin, H., and Li, W. (2021). Risk factors of recurrent erysipelas in adult Chinese patients: A prospective cohort study. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-020-05710-3"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Matych, M., Ciosek, A., Miler, K., Noweta, M., Brzezi\u0144ska, K., Sarza\u0142a, M., Narbutt, J., and Lesiak, A. (2025). Primary and Recurrent Erysipelas-Epidemiological Patterns in a Single-Centre Retrospective Analysis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155299"},{"key":"ref_11","unstructured":"AMBOSS GmbH (2025). Skin and Soft Tissue Infections. AMBOSS, AMBOSS GmbH."},{"key":"ref_12","first-page":"124","article-title":"An Update on the Treatment and Management of Cellulitis","volume":"110","author":"Poehls","year":"2019","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jinf.2023.12.007","article-title":"Development and validation of the Baseline Recurrence Risk in Cellulitis (BRRISC) score","volume":"88","author":"Cross","year":"2024","journal-title":"J. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PRS.0000000000001271","article-title":"Obesity-induced lymphedema: Clinical and lymphoscintigraphic features","volume":"135","author":"Greene","year":"2015","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_15","unstructured":"B\u0105k-Sosnowska, M., Bia\u0142kowska, M., Bogda\u0144ski, P., Chomiuk, T., Dobrowolski, P., Ga\u0142\u0105zka-Sobotka, M., Holecki, M., Jankowska-Zdu\u0144czyk, A., Jarosi\u0144ska, A., and Jezierska, M. (2025, August 30). Zalecenia kliniczne dotycz\u0105ce post\u0119powania u chorych na oty\u0142o\u015b\u0107 2024, Med. Prakt. Wyd. Specj., Available online: https:\/\/ptlo.org.pl\/resources\/data\/forms\/aktualnosci\/258\/ws_ptlo_otylosc_2024_final.pdf."},{"key":"ref_16","unstructured":"AMBOSS GmbH (2024). Lymphedema. AMBOSS, AMBOSS GmbH."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1917197","article-title":"Compression Therapy to Prevent Recurrent Cellulitis of the Leg","volume":"383","author":"Webb","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Executive Committee of the International Society of Lymphology (2020). The diagnosis and treatment of peripheral lymphedema:2020 Consensus Document of the International Society of Lymphology. Lymphology, 53, 3\u201319.","DOI":"10.2458\/lymph.4649"},{"key":"ref_19","first-page":"34","article-title":"Skin integrity, antimicrobial stewardship and infection control: A critical review of current best practice","volume":"32","author":"Blackburn","year":"2024","journal-title":"Wound Pract. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.47.11.3630-3633.2003","article-title":"Doxycycline is anti-Inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines","volume":"47","author":"Krakauer","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e01282-23","DOI":"10.1128\/aac.01282-23","article-title":"Doxycycline versus cephalexin treatment of presumed streptococcal skin and soft tissue infection among adults presenting to the emergency department","volume":"68","author":"Taylor","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ofx232","DOI":"10.1093\/ofid\/ofx232","article-title":"Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess","volume":"4","author":"Bowen","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ACI.0000000000000173","article-title":"Penicillin allergy: Optimizing diagnostic protocols, public health implications, and future research needs","volume":"15","author":"Macy","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.anai.2019.12.016","article-title":"Addressing the epidemic of antibiotic \u201callergy\u201d over-diagnosis","volume":"124","author":"Macy","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_25","first-page":"CD009758","article-title":"Interventions for the prevention of recurrent erysipelas and cellulitis","volume":"6","author":"Dalal","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0163-4453(91)90898-3","article-title":"Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections","volume":"22","author":"Kremer","year":"1991","journal-title":"J. Infect."},{"key":"ref_27","first-page":"E10","article-title":"Low-dose penicillin for recurrent cellulitis?","volume":"63","author":"Nguyen","year":"2014","journal-title":"J. Fam. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/lrb.2020.0051","article-title":"Long-Term Benzathine Penicillin Prophylaxis Lasting for Years Effectively Prevents Recurrence of Dermato-Lymphangio-Adenitis (Cellulitis) in Limb Lymphedema","volume":"19","author":"Olszewski","year":"2021","journal-title":"Lymphat. Res. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"UK Dermatology Clinical Trials Network\u2019s PATCH Trial Team, Thomas, K., Crook, A., Foster, K., Mason, J., Chalmers, J., Bourke, J., Ferguson, A., Level, N., and Nunn, A. (2012). Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: Results of the UK Dermatology Clinical Trials Network\u2019s PATCH II trial. Br. J. Dermatol., 166, 169\u2013178.","DOI":"10.1111\/j.1365-2133.2011.10586.x"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1206300","article-title":"Penicillin to Prevent Recurrent Leg Cellulitis","volume":"368","author":"Thomas","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.32394\/pe.74.06","article-title":"Clinical practice guidelines for Clostridioides (Clostridium) difficile infection and fecal microbiota transplant protocol\u2014Recommendations of the Polish Society of Epidemiology and Infectious Diseases","volume":"74","author":"Piekarska","year":"2020","journal-title":"Przegl. Epidemiol."},{"key":"ref_33","unstructured":"Patel, K., and Goldman, J.L. (2025, August 30). Erythromycin, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532910\/."},{"key":"ref_34","unstructured":"European Medicines Agency (2025, August 30). Azithromycin\u2014Summary of Product Characteristics. Available online: https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h110860_smpc_en.pdf."},{"key":"ref_35","unstructured":"Omran, A., and Wood, M. (2025, August 30). Clarithromycin, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549780\/."},{"key":"ref_36","unstructured":"Ashley, E.A., and Martens, R.J.H. (2025, August 30). Doxycycline, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556117\/."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Berbel, D., Gonz\u00e1lez-D\u00edaz, A., L\u00f3pez de Egea, G., C\u00e0mara, J., and Ardanuy, C. (2022). An Overview of Macrolide Resistance in Streptococci: Prevalence, Mobile Elements and Dynamics. Microorganisms, 10.","DOI":"10.3390\/microorganisms10122316"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Villal\u00f3n, P., B\u00e1rcena, M., Medina-Pascual, M.J., Garrido, N., Pino-Rosa, S., Carrasco, G., and Valdezate, S. (2023). National Surveillance of Tetracycline, Erythromycin, and Clindamycin Resistance in Invasive Streptococcus pyogenes: A Retrospective Study of the Situation in Spain, 2007\u20132020. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010099"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102633","DOI":"10.1016\/j.jiph.2024.102633","article-title":"Antimicrobial resistance and epidemiological patterns of Streptococcus pyogenes in T\u00fcrkiye","volume":"18","author":"Caglayan","year":"2025","journal-title":"J. Infect. Public Health"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Alexandrova, A.S., Muhtarova, A.A., Boyanov, V.S., and Gergova, R.T. (2025). Burden of Streptococcus pyogenes and emm12 Type in Severe Otitis Media Among Children. Microbiol. Res., 16.","DOI":"10.3390\/microbiolres16080181"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11239-019-02013-6","article-title":"The risk of intramuscular haematoma is low following injection of benzathine penicillin G in patients receiving concomitant anticoagulant therapy","volume":"50","author":"Fox","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_42","unstructured":"British Lymphology Society (BLS) (2016). Consensus Document on the Management of Cellulitis in Lymphoedema, BLS. Available online: https:\/\/www.thebls.com\/public\/uploads\/documents\/document-75091530863967.pdf."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2448\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:37:35Z","timestamp":1788431855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biomedicines13102448"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13102448","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}